Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 121,000 shares, a growth of 103.0% from the December 31st total of 59,600 shares. Based on an average daily volume of 153,600 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.5% of the shares of the stock are short sold.

Bolt Biotherapeutics Trading Up 2.4 %

Bolt Biotherapeutics stock traded up $0.01 during trading on Wednesday, hitting $0.51. The company’s stock had a trading volume of 18,354 shares, compared to its average volume of 151,531. The stock’s fifty day moving average is $0.55 and its 200 day moving average is $0.63. Bolt Biotherapeutics has a 1-year low of $0.48 and a 1-year high of $1.56. The stock has a market capitalization of $19.40 million, a price-to-earnings ratio of -0.30 and a beta of 0.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. As a group, equities research analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. FMR LLC lifted its position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,386 shares of the company’s stock after buying an additional 28,773 shares during the period. FMR LLC owned approximately 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. 86.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.